

KENYA

Support for Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Kenya																
2. Vaccine grant number:	19-KEN-08f-Y, 19-KEN-19b-X, 20-KEN-19b-X																
3. Date of Decision Letter:	30-Sep-2019																
4. Date of the Partnership Framework Agreement:	25 November 2014																
5. Programme title:	New Vaccine Support (NVS), HPV, Routine																
6. Vaccine type:	Human Papillomavirus Vaccine																
7. Requested product presentation and formulation of vaccine:	HPV Quadrivalent, 1 dose per vial, LIQUID																
8. Programme Duration:¹	2019-2020																
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)																
	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th></th> <th>2019</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> <th>Total²</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>6,674,000</td> <td>5,977,500</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>12,651,500</td> </tr> </tbody> </table>		2019	2020	2021	2022	2023	2024	Total ²	Programme Budget (US\$)	6,674,000	5,977,500	-	-	-	-	12,651,500
	2019	2020	2021	2022	2023	2024	Total ²										
Programme Budget (US\$)	6,674,000	5,977,500	-	-	-	-	12,651,500										
10. Vaccine introduction grant																	
	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2019</td> <td>19-KEN-08f-Y</td> <td>1,838,897</td> </tr> </tbody> </table>	Approval			Year	Grant Number	Amount (US\$)	2019	19-KEN-08f-Y	1,838,897							
Approval																	
Year	Grant Number	Amount (US\$)															
2019	19-KEN-08f-Y	1,838,897															
11. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)																
	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th>Type of supplies to be purchased with Gavi funds</th> <th>2019</th> <th>2020</th> <th>2021</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>1,466,000</td> <td>1,313,000</td> <td>-</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>6,674,000</td> <td>5,977,500</td> <td>-</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds	2019	2020	2021	Number of vaccine doses	1,466,000	1,313,000	-	Annual Amounts (US\$)	6,674,000	5,977,500	-				
Type of supplies to be purchased with Gavi funds	2019	2020	2021														
Number of vaccine doses	1,466,000	1,313,000	-														
Annual Amounts (US\$)	6,674,000	5,977,500	-														
12. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																
13. Self-procurement:	Not applicable																

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

14. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:

Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	149,600	-	-	-	-
Number of AD syringes	156,700	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	1,750	-	-	-	-
Value of vaccine doses (US\$)	672,790	-	-	-	-
Total co-financing payments (US\$) (including freight)	688,000	-	-	-	-

15. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	Quarterly 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

16. Financial clarifications:

Not applicable

Signed by,
On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30-Sep-2019